+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe IVD In Cardiology And Neurology Market Size, Share & Trends Analysis Report By Product Type, By End Use, By Technology (Immunoassays, Molecular Diagnostics, Hematology, and Others), By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 123 Pages
  • March 2024
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5953698
The Europe IVD In Cardiology And Neurology Market would witness market growth of 8.9% CAGR during the forecast period (2023-2030).

The Germany market dominated the Europe IVD In Cardiology And Neurology Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,778 million by 2030. The UK market is exhibiting a CAGR of 7.9% during (2023 - 2030). Additionally, The France market would experience a CAGR of 9.8% during (2023 - 2030).



The integration of Artificial Intelligence (AI) has transformed the landscape of IVD in cardiology and neurology. AI algorithms enhance diagnostic data interpretation, improving test results' accuracy and efficiency. The utilization of machine learning in image analysis and risk prediction models can significantly transform diagnostic capabilities by furnishing clinicians with cutting-edge decision support tools.

Furthermore, an important benefit of integrating AI into IVD is the significant enhancement in the precision and effectiveness of test outcomes. The rapid processing of enormous volumes of data by machine learning algorithms reduces the probability of human error and improves the accuracy of diagnostic evaluations. In cardiology, AI aids in interpreting cardiac imaging, electrocardiograms (ECGs), and biomarker data. Neurology supports the analysis of neuroimaging, genetic data, and cerebrospinal fluid markers, providing a more comprehensive understanding of neurological conditions.

The European Union has witnessed a continuous commitment to increasing healthcare budgets. This enhanced funding allows for investments in state-of-the-art diagnostic technologies, including those related to In vitro diagnostics. According to the Eurostat data, Germany had the highest level of current healthcare expenditure among the EU Member States, valued at €432 billion in 2020. Following Italy ($160 billion) and Spain ($120 billion) in terms of current healthcare spending was France ($281 billion). Thus, the increasing healthcare expenditure in Europe is expected to boost the region's demand for In vitro diagnostics in cardiology and neurology.

Based on Product Type, the market is segmented into Reagents & Consumables, Instruments, and Software & Services. Based on End Use, the market is segmented into Hospitals, Clinical Laboratories, and Others. Based on Technology, the market is segmented into Immunoassays, Molecular Diagnostics, Hematology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Sysmex Corporation
  • Siemens Healthineers AG (Siemens AG)
  • Quest Diagnostics Incorporated
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (Beckman Coulter, Inc.)
  • Becton, Dickinson and Company
  • Natera, Inc.

Market Report Segmentation

By Product Type
  • Reagents & Consumables
  • Instruments
  • Software & Services
By End Use
  • Hospitals
  • Clinical Laboratories
  • Others
By Technology
  • Immunoassays
  • Molecular Diagnostics
  • Hematology
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe IVD In Cardiology And Neurology Market, by Product Type
1.4.2 Europe IVD In Cardiology And Neurology Market, by End Use
1.4.3 Europe IVD In Cardiology And Neurology Market, by Technology
1.4.4 Europe IVD In Cardiology And Neurology Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Europe IVD In Cardiology And Neurology Market by Product Type
4.1 Europe Reagents & Consumables Market by Country
4.2 Europe Instruments Market by Country
4.3 Europe Software & Services Market by Country
Chapter 5. Europe IVD In Cardiology And Neurology Market by End-use
5.1 Europe Hospitals Market by Country
5.2 Europe Clinical Laboratories Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe IVD In Cardiology And Neurology Market by Technology
6.1 Europe Immunoassays Market by Country
6.2 Europe Molecular Diagnostics Market by Country
6.3 Europe Hematology Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe IVD In Cardiology And Neurology Market by Country
7.1 Germany IVD In Cardiology And Neurology Market
7.1.1 Germany IVD In Cardiology And Neurology Market by Product Type
7.1.2 Germany IVD In Cardiology And Neurology Market by End-use
7.1.3 Germany IVD In Cardiology And Neurology Market by Technology
7.2 UK IVD In Cardiology And Neurology Market
7.2.1 UK IVD In Cardiology And Neurology Market by Product Type
7.2.2 UK IVD In Cardiology And Neurology Market by End-use
7.2.3 UK IVD In Cardiology And Neurology Market by Technology
7.3 France IVD In Cardiology And Neurology Market
7.3.1 France IVD In Cardiology And Neurology Market by Product Type
7.3.2 France IVD In Cardiology And Neurology Market by End-use
7.3.3 France IVD In Cardiology And Neurology Market by Technology
7.4 Russia IVD In Cardiology And Neurology Market
7.4.1 Russia IVD In Cardiology And Neurology Market by Product Type
7.4.2 Russia IVD In Cardiology And Neurology Market by End-use
7.4.3 Russia IVD In Cardiology And Neurology Market by Technology
7.5 Spain IVD In Cardiology And Neurology Market
7.5.1 Spain IVD In Cardiology And Neurology Market by Product Type
7.5.2 Spain IVD In Cardiology And Neurology Market by End-use
7.5.3 Spain IVD In Cardiology And Neurology Market by Technology
7.6 Italy IVD In Cardiology And Neurology Market
7.6.1 Italy IVD In Cardiology And Neurology Market by Product Type
7.6.2 Italy IVD In Cardiology And Neurology Market by End-use
7.6.3 Italy IVD In Cardiology And Neurology Market by Technology
7.7 Rest of Europe IVD In Cardiology And Neurology Market
7.7.1 Rest of Europe IVD In Cardiology And Neurology Market by Product Type
7.7.2 Rest of Europe IVD In Cardiology And Neurology Market by End-use
7.7.3 Rest of Europe IVD In Cardiology And Neurology Market by Technology
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Sysmex Corporation
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Siemens Healthineers AG (Siemens AG)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.6 SWOT Analysis
8.5 Quest Diagnostics Incorporated
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.5.5 SWOT Analysis
8.6 Abbott Laboratories
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Bio-Rad laboratories, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 SWOT Analysis
8.8 Danaher Corporation (Beckman Coulter)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Becton, Dickinson, and Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. Natera Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis

Companies Mentioned

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sysmex Corporation
  • Siemens Healthineers AG (Siemens AG)
  • Quest Diagnostics Incorporated
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (Beckman Coulter, Inc.)
  • Becton, Dickinson and Company
  • Natera, Inc.

Methodology

Loading
LOADING...